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Background: Chronic musculoskeletal pain may be associated with changes in the balance of algogenic and anti-
nociceptive compounds, and such changes may be visible in plasma samples. We have undertaken an exploratory
study to measure the levels of endocannabinoids, related N-acylethanolamines and oxylipins (primarily those
derived from linoleic acid) in plasma samples from women with chronic neck pain (NP) and chronic widespread
pain (CWP), and to investigate whether the observed levels are associated with the pain experienced by these
women.
Methods: Blood samples from 35 women with NP, 15 with CWP and 27 age-matched controls were analysed for
the lipids using ultra performance liquid chromatography coupled to tandem mass spectrometry. Current pain
(“NRSday”) and the average pain during the last week (“NRSweek”) were rated by the participants using a numerical
rating scale.
Results: There were no significant differences in the plasma concentrations of the fifteen lipids investigated
between the women with pain and the controls. However, significant correlations were seen for the NP group
between the NRSday scores and the plasma concentrations of the linoleic acid derivatives 9- and 13-hydroxy-
octadecadienoic acid (Spearman’s rho values 0.51 [P = 0.0016]) and 0.53 [P = 0.0011], respectively).
Conclusions: The data obtained in this exploratory study indicate that although no group differences are seen in
plasma lipid concentrations, there is an association between the NRSday scores and the 9- and 13-hydroxy-
octadecadienoic acid levels. Whether or not the association reflects a causality (i.e. that the circulating lipids
contribute to the perceived pain of the pain participants), requires further investigation.
Keywords: Musculoskeletal disorders, chronic neck pain, chronic widespread pain, endocannabinoids, N-
acylethanolamines, oxylipins, 9-hydroxy-10E,12Z-octadecadienoic acid, 13-hydroxy-9Z,11E-octadecadienoic acidBackground
Chronic pain is a very common condition with a large
cost to society both in economic and personal terms.
Chronic pain, which most often presents as musculo-
skeletal pain, can be either localised to defined struc-
tures or areas or have a more widespread occurrence.
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to the neck (NP) was the fourth ranked disorder with re-
spect to years lived with disability in the USA during the
period 1990–2010 [1]. Chronic widespread pain (CWP),
defined by the American College of Rheumatology as
pain present on both sides of the body as well as both
above and below the waist [2, 3] is also very common,
with a prevalence in the range 4.8–7.4 % of the popula-
tion [4]. The pain in CWP and NP has both central and
peripheral components, and at the level of the muscle,
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estingly, the raised interstitial concentrations of glutam-
ate and lactate seen in muscle dialysates from CWP
patients were also seen in plasma from the same individ-
uals [5]. In another microdialysis study investigating
controls and individuals with trapezius myalgia, a posi-
tive correlation was seen between baseline pain and the
interstitial levels of serotonin, an important pain-
signalling molecule [6].
Endogenous pain modulation is not restricted to glu-
tamate, lactate and serotonin alone, and there are a num-
ber of lipids, including N-acylethanolamines (NAEs),
endocannabinoids and oxylipins derived from linoleic acid
that affect pain perception. With respect to the NAEs, the
most well-studied is arachidonoylethanolamide (AEA,
anandamide), which produces its actions in the body pri-
marily via effects upon cannabinoid (CB) receptors,
although it can also act upon transient receptor potential
vanilloid 1 (TRPV1) receptors, particularly under condi-
tions of inflammation [7]. A related compound, 2-
arachidonoylglycerol (2-AG) is also an endocannabinoid,
and compounds inhibiting the hydrolysis of either AEA or
2-AG are active in a wide variety of animal models of pain
[8, 9]. The NAE palmitoylethanolamide (PEA) is not an
endocannabinoid, but produces analgesia purportedly by
activation of peroxisome proliferator-activated receptor α
[10]. Oleoylethanolamide (OEA) also affects pain, albeit
by a mechanism independent of peroxisome proliferator-
activated receptor α [11]. In addition to its analgesic
effects, PEA is anti-inflammatory, a property shared by
stearoylethanolamide (SEA) [12]. Other members of the
NAE family, such as linoleoylethanolamide (LEA), are less
well investigated.
Relatively little is known about NAE/2-AG levels in hu-
man musculoskeletal pain. However, in trapezius muscle
microdialysates, levels of PEA and SEA are increased in
chronic neck/shoulder pain, but not in CWP [13]. It is not
known whether changes in the levels of these NAEs are
seen in the plasma of individuals with CWP and/or chronic
neck pain (NP). A large increase in plasma AEA, however,
has been reported in patients with fibromyalgia [14].
Oxylipins derived from linoleic acid are another import-
ant class of biologically active lipids. In plasma, among the
most prevalent are 9-HODE (9-hydroxy-10E,12Z-octade-
cadienoic acid) and 13-HODE (13-hydroxy-9Z,11E-octa-
decadienoic acid). To our knowledge, it is not known
whether plasma/serum levels of the HODEs or related
lipids are changed in human musculoskeletal pain, but
they are increased in other pain conditions, such as
Achilles tendinopathy [15]. Given the ability of these com-
pounds to activate TRPV1 receptors involved in pain
transmission [16, 17], it is possible that the increased
levels of these lipids may contribute to the pain found in
these disorders.From the above, it can be argued that chronic muscu-
loskeletal pain may be associated with changes in the
balance of algogenic and anti-nociceptive compounds,
and that such changes may be visible in plasma samples.
In consequence, given the lack of knowledge in this area,
we have undertaken an exploratory study to measure the
levels of AEA, 2-AG, related NAEs and linoleic acid-
derived oxylipins in plasma samples from healthy
women, women with CWP and NP, and to investigate
whether the observed levels are associated with the pain
experienced by these individuals.
Methods
Subjects
Female participants of age range 20–65 years were con-
secutively recruited during the period June 2011–March
2012. Twenty-seven healthy controls and 36 subjects
with NP (of whom data from 35 are reported here) were
recruited from a randomized controlled trial (Current
Controlled Trials registration ISRCTN49348025; the
trial comprised 120 subjects with NP and 40 healthy
controls) [18]. Seventeen subjects with CWP (of whom
data from 15 are reported here) were recruited via contact
with the local patient organisation and/or advertising in
local newspapers. Ethical approval for this project was
granted by the ethical committee of Uppsala University
(registration number 2011/081). All subjects participated
voluntarily after informed written consent. For the NP
group, inclusion criteria were more than 6 weeks of non-
specific neck-shoulder pain (indicated as dominant pain
area in a pain drawing), more than “no disability” but less
than “complete disability” according to the Neck Disability
Index (NDI), and self-reported impaired productivity to
work the preceding month (for details see [18]). The CWP
group had obtained their diagnosis using the American
College of Rheumatology criteria for fibromyalgia [2] al-
beit without the requirement of at least 11/18 trigger
points. Subjects with rheumatoid arthritis, systemic lupus
erythematosus, Bechterew’s disease, multiple sclerosis, epi-
lepsy or Parkinson’s disease, type I-diabetes, cardiovascu-
lar disease or endocrine diseases were excluded, as were
subjects who did not eat either fish or meat on a regular
basis.
All participants were asked not to use any pain medica-
tions except for paracetamol preparations three days be-
fore the blood sampling and to avoid intake of caffeine,
nicotine and wholegrain during the 12 h prior to blood
sampling. The subjects were allowed water alone during
the last two hours of this period and were also asked not
to perform any shoulder or neck-straining exercises for
the last two days prior to blood sampling, except for or-
dinary daily work and/or leisure activities. All subjects
rated the current pain (“NRSday”) and the average pain
during the last week (“NRSweek”) on a numerical rating
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pain imaginable) at the time of blood sample collection.
NRS is adjudged to have a higher validity than several
other commonly used pain scores [20].
Blood sampling procedure
Blood was sampled either during the morning (between
07:30 and 11:30) or afternoon (between 12:00 and
15:00). After arrival at the laboratory, subjects were
allowed to rest for 15 min before venous blood was
drawn into Li-Heparin prepared Vacutainer tubes from
the bend of the arm while the subjects were in a sitting
position. Blood for plasma analysis were treated according
to a standardised protocol, whereby the Vacutainer tube
was turned 10 times during a 30 s period at room
temperature before being immediately centrifuged at 4 °C
for 5 min at 2500 rpm. Supernatants were aliquoted
(500 μL) into pre- labelled homopolymer tubes and frozen
at −80 °C until analysis. Thus, the lipid analyses conducted
here were undertaken on previously unthawed samples.
Chemicals and reagents for lipid analyses
The following native and deuterated standards were pur-
chased from Cayman Chemical (Ann Arbor, MI, USA): 2-
AG, AEA, PEA, SEA, OEA, LEA, 9-HODE, 13-HODE,
9(10)-DiHOME (9(10)-dihydroxy-12Z-octadecenoic acid),
12(13)-DiHOME (12(13)-dihydroxy-9Z-octadecenoic acid),
13-oxo-ODE (13-oxo-9Z,11E-octadecadienoic acid), 5-
HETE (5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid), 8,9-
DiHETrE (8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic acid), 1
2-[[(cyclohexylamino)carbonyl]amino]-dodecanoic acid
(CUDA), 2-AG-d8, AEA-d8, PEA-d4, SEA-d3, OEA-d4,
TXB2-d4, 12(13)-DiHOME-d4, 9(S)-HODE-d4, 20-HETE-
d4, 5(S)-HETE-d8 and 12(13)-EpOME-d4. 9,10,13-Tri-
HOME (9,10,13-trihydroxy-11-octadecenoic acid) and
9,12,13-TriHOME (9,12,13-trihydroxy-10E-octadecenoic
acid) were obtained from Larodan (Sweden, Malmö).
Butylhydroxytoluene (BHT) was obtained from the Cay-
man Chemical Co. All solvents and chemicals used were
of HPLC grade or higher. A Milli-Q Gradient system
(Millipore, Milford, MA, USA) was used to purify water.
The deuterated compounds were used as internal stan-
dards and added prior to extraction to mimic the isola-
tion of the endogenous compounds from the plasma
samples. For each native compound, a suitable internal
standard was selected based on structural similarities for
quantification purposes. Recovery rates of each internal
standard were calculated by adding a known amount of
the recovery standard CUDA in the last step before injec-
tion. The recovery rates (%, means ± SD) of the internal
standards in the present study were: 2-AG-d8 (92.3 ± 13.3,
N = 74), AEA-d8 (70.7 ± 11.3, N = 74), PEA-d4 (70.0 ± 21.8,
N = 74), SEA-d3 (71.2 ± 6.2, N = 74), OEA-d4 (62.1 ± 13.7,
N = 74), TXB2-d4 (71.7 ± 16.6, N = 74), 12(13)-DiHOME-d4(77.2 ± 10.2, N = 74), 9(S)-HODE-d4 (67.5 ± 16.4, N = 74),
20-HETE-d4 (101.3 ± 12.2, N = 74), 5(S)-HETE-d8
(81.1 ± 14.7, N = 74) and 12(13)-EpOME-d4 (103.7 ±
13.7, N = 74).
Lipid extraction and analyses
A previously reported and validated SPE protocol was used
for isolation of the lipids [21]. In brief, plasma samples
(400 μL) were thawed on ice and spiked with 10 μL internal
standards solutions and 10 μL antioxidant (0.2 mg/mL
BHT/EDTA in methanol:water (1:1)) solution before being
extracted using Waters Oasis HLB cartridges (60 mg of sor-
bent, 30 μm particle size). Eluates were reconstituted in
100 μL of MeOH spiked with 10 μL CUDA (0.05 μg/mL)
and transferred to vials before analysis using an ultra per-
formance liquid chromatography coupled to tandem mass
spectrometry (UPLC-MS/MS) method.
Lipid analyses were undertaken on an Agilent UPLC
(Infinity 1290) coupled with an electrospray ionization
(ESI) source to an Agilent 6490 Triple Quadrupole sys-
tem equipped with the iFunnel Technology (Agilent
Technologies, Santa Clara, CA, USA). Analyte separ-
ation was achieved using a Waters BEH C18 column
(2.1 mm x 150 mm, 130 Å, 1.7 μm particle size) accord-
ing to a previously validated analytical protocol [21]. In-
jection volumes of 10 μL were employed, and the mobile
phases consisted of (A) 0.1 % acetic acid in MilliQ
water and (B) acetonitrile:isopropanol (90:10). For the
endocannabinoids and related NAEs, the system
operated in positive mode (ESI+) with the following
gradient: 0.0–2.0 min 30–45 % B, 2.0–2.5 min 45–79 %
B, 2.5–11.5 min 79 % B, 11.5–12 min 79–90 % B, 12–
14 min 90 % B, 14–14.5 min 90–79 % B, 14.5–15.5 min
79 % B, 15.6–19 min 30 % B. For the linoleic acid- and
arachidonic acid-derived oxylipins, the negative ionisa-
tion mode was used (ESI-), with the following gradient:
0.0–3.5 min 10–35 % B, 3.5–5.5 min 40 % B, 5.5–
7.0 min 42% B, 7.0–9.0 min 50 % B, 9.0–15.0 min 65 %
B, 15.0–17.0 min 75 % B, 17.0–18.5 min 85 % B, 18.5–
19.5 min 95 % B, 19.5–21 min 95-10 % B, 21.0–25.0 min
10 % B. The dynamic multiple reaction monitoring
(dMRM) option was performed for the lipids with opti-
mized transitions and collision energies [21]. All peaks
were integrated manually using the MassHunter Work-
station software, and the stable isotope dilution method
was used to quantify the peaks using calibration curves of
peak areas of native compounds divided by the corre-
sponding IS peak areas. Accuracy and precision for
the method is described elsewhere [21], but in general
at the levels detected in the current study the preci-
sion ranged from 4.6–9.8 % (endocannabinoids and
related NAEs) and 2.1–11.2 % (oxylipins) and accur-
acies ranged from 98–119 % (endocannabinoids and
related NAEs) to 100–111 % (oxylipins).
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Groups (both patient characteristics and outcome vari-
ables) were tested for normal distribution using the
D’Agostino and Pearson normality test and differences
between groups were tested using Kruskal-Wallis test,
Mann Whintney U-test or Chi squared test, all using
GraphPad Prism v. 6 for the Macintosh (GraphPad Soft-
ware Inc., San Diego, CA, USA). Statistical analysis of
the effects of sampling time and pain group upon the
observed lipid concentrations were undertaken using
two-way robust Wilcoxon analyses (available with the
function raov in the Rfit package version 0.22 of the R
computer programme [22, 23]). Correlations between
AEA, 2-AG, related NAEs and linoleic acid-derived oxyli-
pins and self rated pain scores were conducted with Spear-
man’s correlation coefficients (GraphPad Software). For
comparison between independent correlation coefficients,
the standard Fisher’s transformation was used with an on-
line calculator (http://vassarstats.net/index.html, URL
checked on 19 February 2016). The false discovery rate
(FDR) by Benjamin and Hochberg [24] was used to con-
trol for the expected proportion (5 %) of incorrectly




Subject characteristics are presented in Table 1. There
were no significant differences in the distribution of
the time of day of sampling (morning vs. afternoon),
the body weight, BMI and number of nicotine users
among the subjects. A significant group difference for
age was seen, due to a difference between the CWP
and NP groups (CWP > NP, P < 0.05, Dunn’s multipleTable 1 Subject characteristics. Data for background variables are prese
were used since there was an unequal distribution in the number of sub
in many cases (e.g. body weight), the data were not normally distributed
percent in group
Control (n = 27) Localised neck pain (N
Age [years] 52 (25–61) 49 (26–64)
Height [cm] 166 (158–180) 167 (156–177)
Weight [kg] 64 (50–88) -1 64 (51–100) −1
BMI [kg x m2] 23 (19–31) −1 24 (19–32) −1
NRSday - 2 (1–6)
NRSweek - 4 (1–8)
Pain duration [months] - 42 (5–288) −1
Nicotine users [No.] 4 (15 %) 4 (11 %)
Sampling timed 15 M, 12A 17 M, 17A−1
In the table, the superscripts −1 and −2 indicate the number of missing data for th
weight was only available for 26 controls
BMI Body mass index, NRS numerical rating scale 0–10. Statistical tests, p-value < 0.0
a Kruskal-Wallis test, b Mann–Whitney-U test, cChi squared test, excluding the cases
and afternoon (A)comparisons post-hoc test). The scores for the average
pain during the last week (“NRSweek”) were greater for
the CWP group than the NP group, whereas the
current pain scores (“NRSday”) were not significantly
different between the two groups.
Plasma levels of endocannabinoids, related NAEs and
linoleic acid-derived oxylipins in controls and subjects
with CWP and NP
Plasma levels of fifteen lipids (AEA and 2-AG, four re-
lated NAEs, and seven linoleic acid-derived oxylipins in-
cluding 9- and 13-HODE, and two arachidonic acid-
derived oxylipins, 5-HETE and 8,9- DiHETrE) were
quantified in serum samples from 27 controls, 15
women with CWP and 35 women with NP. The plasma
concentrations of 9- and 13-HODE were highly correlated
for all three groups (P for Spearman rank correlation co-
efficients <0.001, Fig. 1a) and a similar pattern was seen
for the correlation between the two NAEs PEA and SEA
(Fig. 1b). In contrast, the plasma concentrations of the
two endocannabinoids were not significantly correlated
(Fig. 1c). This is not merely a reflection of potential quan-
tification issues for the low abundant AEA, since 9,10,13-
TriHOME, which has a similar abundance to AEA, is very
highly correlated to 9,12-13-TriHOME, which has a simi-
lar abundance to 2-AG (Fig. 1d).
The median values and interquartile ranges are shown
for all fifteen lipids in Table 2, stratified both on the basis
of the condition (control, NP, CWP) and of the time of
sampling (morning and afternoon). The P values for two-
way robust Wilcoxon analyses [22, 23] are also given in
the Table. In no case did the ANOVA P values for the
condition as main effect reach significance. Significant in-
teractions were seen for the condition × time of samplingnted with median and range for all groups. Non-parametric statistics
jects between the CWP group and the other two groups, and since
. The number of nicotine users is presented as the numbers and
P, n = 35) Chronic widespread pain (CWP, n = 15) P-value
58 (41–65) 0.029a
168 (153–177) −2 0.73a
67 (55–110) −2 0.82a
24 (21–38) −2 0.59a
3 (1–8) 0.28b
6 (2–7) 0.016b
222 (120–420) −1 <0.0001b
3 (20 %) 0.73c
5 M, 9A−1 0.48c
e variable and group in question. Thus, for example, information on body
5 is considered significant
when sampling time was not known. dSampling time is shown as morning (M)
Fig. 1 Individual values of a 9- and 13-HODE; b PEA and SEA; c 2-AG and AEA; and d 9,10,13-TriHOME and 9,12,13-TriHOME for the controls
(N = 27), NP (N = 35) and CWP (N = 15) participants. The Spearman’s rho values for the correlation between the lipid pairs for controls, NP and
CWP participants, respectively, were: Panel a 0.91, 0.78 and 0.88, all P < 0.001); Panel b 0.70 [P < 0.0001], 0.49 [P = 0.0028] and 0.70 [P = 0.0048];
Panel c 0.23, 0.13 and 0.32, all P > 0.2); Panel d 0.86 [P < 0.0001], 0.85 [P < 0.0001] and 0.74 [P = 0.0023]
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these levels were below the threshold for significance
upon implementation of the false discovery rate approach
of Benjamini and Hochberg [24]. A similar result was seen
when the cases were stratified into two BMI groups: BMI
in the normal range (18.5–24.9 kg/m2; N = 57 in total) and
overweight/obese (BMI ≥25 kg/m2; N = 22 in total; only 6
individuals were obese [BMI ≥30 kg/m2] and this was ad-
judged to be a too small sample size). The main effect of
condition again did not reach significance for any of the
lipids (P > 0.27) and the only significant finding was an
interaction condition × BMI for AEA (P = 0.027, otherwise
P > 0.14 for the interactions, two-way robust Wilcoxon
analyses).
Association of the plasma levels of endocannabinoids,
related NAEs and linoleic acid-derived oxylipins with the
NRS pain scores for the CWP and NP patients
The patients were asked to rate their pain on the day of
blood sampling (“NRSday”) and for the week prior to the
blood sampling (“NRSweek”). The NRSday and NRSweek
scores (median, with range in brackets) for the NP group
were 2 (1–6) and 4 (1–8), respectively. The correspond-
ing scores for the CWP group were 3 (1–8) and 6 (2–7),
respectively (Table 1).
Bivariate (zero-order) Spearman rank correlation coef-
ficients were calculated for the correlations between the
lipid concentrations and the NRSday scores for the CWPand NP patients. An example of the raw data is shown
for 9-HODE in Fig. 2a, and the correlation coefficients
are given in Table 3 and presented visually in Fig. 2b and
c. The data points are colour coded on the basis of their
group (orange for the linoleic acid-derived oxylipins, red
for the endocannabinoids, blue for the related NAE’s
and yellow for the two arachidonic acid-derived oxyli-
pins). Given that there are multiple comparisons, we
have presented the significance levels “as is”, showing
two vertical lines: one at P = 0.05, and one at P = 0.0033,
which represents the limit using the false discovery rate
approach of Benjamini and Hochberg [24] for the 30
comparisons. For the NP cases, five of the linoleic acid-
derived oxylipins (from left to right in Fig. 2b: 13-
HODE, 9-HODE, 13-oxo-ODE, 12,13-DiHOME and
9,10-DiHOME) reached significance at the P < 0.05 level,
and the P values for the two HODEs were smaller than
the 5 % Benjamini and Hochberg [24] cut-off value. For
the CWP cases, none of the correlations reached signifi-
cance (Fig. 2b). However, it is important to consider the
significance of the difference rather than the difference
in the significance [25]. Using the Fisher r-to-z transform-
ation, the significance of the differences for the correlation
coefficients for 9- and 13-HODE, 9,10- and 12,13-
DiHOME and 13-oxo-ODE were determined. In no case
was the difference significant (P > 0.13). In consequence,
we have also presented the data for the combined NP +
CWP groups in Table 3.
Table 2 Levels of endocannabinoids, linoleic acid-related oxylipins and related lipids in blood samples from controls and subjects
with CWP or NP
Morning sampling Afternoon sampling
Lipid Condition Median iqr Median iqr P value
2-AG Control 5382 4342 6386 11471 C: 0.35
NP 4325 4139 4820 3483 T: 0.047
CWP 3279 2865 8303 14621 C x T: 0.17
AEA Control 179 63 189 140 C: 0.14
NP 260 195 217 121 T: 0.50
CWP 156 215 221 227 C x T: 0.21
PEA Control 1930 714 2728 1197 C: 0.35
NP 3153 1531 2726 1263 T: 0.19
CWP 2084 1510 2961 2266 C x T: 0.074
SEA Control 8439 5048 11220 5427 C: 0.97
NP 9060 5435 9982 5219 T: 0.072
CWP 11310 11256 10690 7528 C x T: 0.56
OEA Control 926 1685 1767 988 C: 0.20
NP 1861 1145 1761 1009 T: 0.81
CWP 1760 1364 1291 1875 C x T: 0.080
LEA Control 619 184 950 455 C: 0.39
NP 961 425 780 431 T: 0.32
CWP 619 806 710 1220 C x T: 0.024
9-HODE Control 13247 31114 26587 20201 C: 0.75
NP 23724 11755 13251 16879 T: 0.73
CWP 23943 36239 17527 29853 C x T: 0.11
13-HODE Control 35679 43458 43935 37629 C: 0.22
NP 39311 13634 20330 17000 T: 0.49
CWP 24137 44109 17188 36591 C x T: 0.12
9,10-DiHOME Control 4498 12601 7585 12910 C: 0.49
NP 6494 8772 4056 4132 T: 0.39
CWP 3294 13986 2054 4791 C x T: 0.32
12,13-DiHOME Control 15725 15768 15935 14365 C: 0.24
NP 13637 7522 10021 11471 T: 0.57
CWP 9716 14338 5342 12263 C x T: 0.70
9,10,13-TriHOME Control 214 189 284 144 C: 0.63
NP 201 239 289 209 T: 0.36
CWP 210 171 221 163 C x T: 0.85
9,12,13-TriHOME Control 2131 3191 3731 4845 C: 0.98
NP 1657 4282 4173 6797 T: 0.41
CWP 3007 2834 2761 5927 C x T: 0.51
13-oxo-ODE Control 1485 1002 1477 1799 C: 0.51
NP 1781 1513 1146 1498 T: 0.64
CWP 1188 2179 1280 1423 C x T: 0.049
5-HETE Control 718 437 1065 761 C: 0.93
NP 907 692 766 538 T: 0.28
CWP 745 770 852 822 C x T: 0.10
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Table 2 Levels of endocannabinoids, linoleic acid-related oxylipins and related lipids in blood samples from controls and subjects
with CWP or NP (Continued)
8,9-DiHETrE Control 145 55 146 45 C: 0.39
NP 180 74 156 56 T: 0.18
CWP 164 171 125 123 C x T: 0.77
Data are given as medians and the interquartile ranges (iqr) for the concentrations in pM. The sample sizes for the samples taken during the morning and
afternoon, respectively, were: control, 15 and 12; NP, 17 and 17; CWP 5 and 9. P values from two-way robust Wilcoxon analyses [22, 23] show main effects of
condition (“C”), sampling time (“T”) and the interaction C × T. P values <0.05 are shown in bold text
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correlation coefficients for the NP cases taking into ac-
count the exact time of sampling (N = 31; in the
remaining four cases, the exact time of sampling was
not available in the dataset) and the BMI (N = 34). The
correlation coefficients were very similar to the bivariate
coefficients between the lipids and the NRSday scores, in-
dicating that the findings described above are retained
when controlled for time of sampling or for the BMI of
the individuals. Further, first-order Spearman rank cor-
relation coefficients for the NP cases were not changed
when controlling for either age (0.52 and 0.56, N = 35)
or pain duration (0.52 and 0.53, N = 34; data for 9- and
13-HODE, respectively).
Spearman rank correlation coefficients were also cal-
culated for the NP, CWP and NP + CWP groups for the
correlation between all the lipid concentrations and the
NRSweek scores and pain duration. In no case was a sig-
nificant correlation found (see Table 3 for the combined
NP + CWP groups).
Discussion
In the present study, we have utilised a series of blood
plasma samples to assess whether differences in endo-
cannabinoids, related NAEs and/or linoleic acid-derived
oxylipins are seen in participants with NP or CWP, and
whether the blood plasma levels of these lipids are asso-
ciated with the pain experienced by the participants. The
participants were well-characterised with respect both toFig. 2 Panel a 9-HODE concentrations for the pain group samples plotted
between the fifteen lipids studied and the NRSday scores for B, NP and C, C
limits for the lipids colour-coded on the basis of their group: orange for lin
NAEs and yellow for arachidonic acid-derived oxylipins. The x-axes are the
lines showing cut-offs at P = 0.0033 (the Benjamini and Hochberg [24] 5 % fal
c, the value for 8,9- DiHETrE (rho 0.14, P = 0.41) is hidden behind another datatheir current pain and to their ongoing pain, and a strict
blood sampling protocol was used whereby blood was
rapidly cooled, processed at 4 °C and stored at −80 °C.
Limitations of the study are the relatively small sample
sizes, given its exploratory nature, and the fact that since
the samples were originally taken as part of a different
study, the time of sampling was not optimised for an
analysis of the lipids investigated here. However, we have
controlled for this by including morning/afternoon as a
factor in our analyses of the whole group and by under-
taking first order correlations between the NRSday scores
with the lipid levels controlling for the exact time of
sampling for the CWP group. A similar approach was
also used to rule out BMI as a potential confounding
factor. Nevertheless, effects of other factors, such as dif-
ferences in food intake, physical activities and other co-
morbid disease upon the observed plasma levels of the
lipids cannot be ruled out.
With respect to the comparisons between controls and
the pain groups, no significant changes in lipid levels
were seen. The only study, to our knowledge, investigat-
ing the current lipids in blood from cases of this type
was that of Kaufmann et al. [14], who found a consider-
ably higher AEA concentration in the plasma of 22 indi-
viduals with fibromyalgia (17 ♀, 5 ♂, average age
51 years) than for 22 healthy volunteers (17 ♀, 5 ♂, aver-
age age 53 years). Although that study used volunteers
of both genders, whereas our study was confined to
women, the most likely explanation for the differenceagainst the NRSday scores. Panels b and c non-parametric correlations
WP participants. The y-axes show the values and 95 % confidence
oleic acid-derived oxylipins, red for endocannabinoids, blue for related
corresponding P values for the correlation coefficients, with the vertical
se discovery rate limit for the dataset) and at P = 0.05. Note that in Panel
point
Table 3 Spearman’s zero- and first-order Spearman rank correlation coefficients between the pain scores and the plasma lipid
concentrations
Parameter: NRSday NRSday NRSday NRSweek Pain duration
Pain Group: NP CWP NP + CWP NP + CWP NP + CWP
Controlling for: - time BMI - - - -
N: 35 31 34 15 50 50 48
2-AG 0.05 0.06 0.14 −0.43 −0.10 −0.08 0.07
AEA 0.16 0.13 0.23 0.14 0.11 0.22 −0.05
PEA −0.03 0.03 −0.01 0.21 0.01 0.12 −0.10
SEA 0.14 0.23 0.18 0.12 0.13 0.05 −0.07
OEA 0.20 0.23 0.16 0.39 0.25 0.16 −0.10
LEA 0.08 0.14 0.05 0.15 0.11 0.23 −0.17
9-HODE 0.51** 0.49** 0.56*** 0.28 0.43** 0.06 0.06
13-HODE 0.53** 0.54** 0.54** 0.13 0.35* −0.01 −0.12
9,10-DiHOME 0.34* 0.33 0.30 −0.13 0.11 0.06 −0.19
12,13-DiHOME 0.36* 0.34 0.33 −0.10 0.13 0.07 −0.16
9,10,13-TriHOME 0.09 0.06 0.05 0.32 0.13 −0.10 −0.08
9,12,13-TriHOME 0.22 0.14 0.20 0.16 0.19 −0.08 0.01
13-oxo-ODE 0.40* 0.38* 0.46** −0.08 0.23 0.05 −0.15
5-HETE 0.00 −0.06 0.04 −0.14 −0.03 0.02 0.08
8,9-DiHETrE 0.15 0.11 0.18 0.15 0.12 0.09 −0.01
Zero-order correlations are shown where the symbol “-“is given in the row “Controlling for”. First-order correlations controlling for the exact time of day of
sampling or for BM were calculated according to the method of Lehmann [33]
***P < 0.001, **P < 0.01, *P < 0.05, otherwise not significant
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choice of the patients. Both studies investigated partici-
pants with long-standing disease (>10 years). The indi-
viduals in the Kaufmann et al. [14] study scored highly
in the fibromyalgia impact questionnaire and had sub-
jective pain scores of 6.4 ± 1.4 (mean ± SEM) as assessed
by a visual analogue scale. Our study investigated patients
defined as CWP rather than specifically as fibromyalgia,
i.e. a potentially more heterogeneous population, and had
median NRSday scores of 3.
Perhaps the most interesting result of the present
study is the positive association between 9- and 13-
HODE levels and the NRSday scores. The fact that both
HODEs reached similar significances is not surprising
given the high correlation between their plasma values
(Fig. 1a). As pointed out earlier, a significant association
does not imply causality, and so both NRSday scores→
HODE levels and HODE levels→NRSday scores should
be considered, as should the possibility that a third fac-
tor affects both NRSday scores and HODE levels, thereby
inducing a significant correlation between these two var-
iables. A recent report in this Journal presented evidence
of ongoing inflammatory processes in individuals with
work related neck/shoulder complaints [26]. In healthy
individuals and in patients with asthma, a chronic in-
flammatory disease, provocation by exposure to subway
air leads to increased levels of linoleic acid-derivedoxylipins in bronchoalveolar lavage samples [27]. Abnor-
mal levels of linoleic acid-derived oxylipins are seen in
blood serum from patients with Achilles tendinopathy
[15], and an increased rate of oxylipin production from
linoleic acid is seen in dental pulp samples from patients
with inflammatory dental pain [28]. However, in the
present study, plasma HODE levels were not signifi-
cantly different between groups and in participants with
pain. In any case, the source of these lipids is not solely
from the affected region of the body, and so the data
cannot shed light upon the underlying pathology of the
pain conditions.
With respect to HODE levels→NRSday scores, both 9-
and 13-HODE are capable of activating TRPV1 receptors
on capsaicin-sensitive trigeminal neurons [16] and the use
of either antibodies to the two HODE derivatives or a
TRPV1 antagonist reduces the allodynia produced by
thermal injury to the rat paw [29]. In our view, a more
likely explanation of our findings, given that hyperalgesia
is a feature of neck pain [30], is that the participants with
pain are more sensitive than the healthy controls to the
local nociceptive effects of normal levels of circulating
HODEs upon TRPV1 receptors, and thereby show the as-
sociations that we have found. Certainly, in animal
models, persistant nociception triggered by nerve growth
factor results in increased nociceptive responses to TRPV1
activation by capsaicin [31], and inflammation of the
Hellström et al. BMC Musculoskeletal Disorders  (2016) 17:103 Page 9 of 10masseter muscle increases TRPV1 expression in the in-
flamed muscle, but not in the contralateral muscle [32].
Although this is an attractive (albeit tenuous) hypothesis,
it is based on our exploratory data and further investiga-
tions, preferably in studies with longitudinal designs, into
the link between musculoskeletal pain and circulating oxy-
lipins are clearly necessary.
Conclusions
The present study has reported an association between
the NRSday scores and the plasma levels of two linoleic
acid derivatives, 9- and 13-HODE, in individuals with
localised musculoskeletal pain. These data motivate
further studies into the role(s) of these oxylipins in
musculoskeletal pain.
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